Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience.
colorectal surgery
inflammatory bowel disease
vedolizumab
Journal
Gastroenterology report
ISSN: 2052-0034
Titre abrégé: Gastroenterol Rep (Oxf)
Pays: England
ID NLM: 101620508
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
13
02
2019
accepted:
06
05
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
7
11
2019
Statut:
epublish
Résumé
Patients with inflammatory bowel diseases frequently require surgery, but immunotherapies used in disease management may increase the risk of post-operative complications. We investigated frequencies of post-operative complications in patients who received vedolizumab-a gut-selective antibody approved for the treatment of moderately to severely active ulcerative colitis and Crohn's disease-in clinical-trial and post-marketing settings. This post hoc analysis of safety data from GEMINI 1, GEMINI 2, and long-term safety studies included patients who had had colectomy or bowel surgery/resection. Data from the post-marketing Vedolizumab Global Safety Database were also analysed (data cutoff point: 19 May 2016). Adverse events relating to post-operative complications were identified using Of 58 total surgeries in patients included in GEMINI 1 and GEMINI 2, post-operative complications were reported for 3/51 vedolizumab-treated patients (5.9%) and 1/7 placebo-treated patients (14.3%). In the long-term safety study, 157/2,243 patients (7%) had colectomy or bowel surgery/resection; of these 157 patients who underwent surgery, 11 (7%) experienced a post-operative complication. Median time between last pre-operative vedolizumab dose and surgery was 23 days in GEMINI 1, 20 days in GEMINI 2, and 39‒40 days in the long-term safety study. In the post-marketing setting, based on data covering approximately 46,978 patient-years of vedolizumab exposure, post-operative complications were reported in 19 patients. In clinical trials, complications of colectomy and bowel surgery/resection appeared infrequent, with minimal difference between vedolizumab and placebo. The frequency of post-operative complications in the post-marketing setting appears low.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with inflammatory bowel diseases frequently require surgery, but immunotherapies used in disease management may increase the risk of post-operative complications. We investigated frequencies of post-operative complications in patients who received vedolizumab-a gut-selective antibody approved for the treatment of moderately to severely active ulcerative colitis and Crohn's disease-in clinical-trial and post-marketing settings.
METHODS
METHODS
This post hoc analysis of safety data from GEMINI 1, GEMINI 2, and long-term safety studies included patients who had had colectomy or bowel surgery/resection. Data from the post-marketing Vedolizumab Global Safety Database were also analysed (data cutoff point: 19 May 2016). Adverse events relating to post-operative complications were identified using
RESULTS
RESULTS
Of 58 total surgeries in patients included in GEMINI 1 and GEMINI 2, post-operative complications were reported for 3/51 vedolizumab-treated patients (5.9%) and 1/7 placebo-treated patients (14.3%). In the long-term safety study, 157/2,243 patients (7%) had colectomy or bowel surgery/resection; of these 157 patients who underwent surgery, 11 (7%) experienced a post-operative complication. Median time between last pre-operative vedolizumab dose and surgery was 23 days in GEMINI 1, 20 days in GEMINI 2, and 39‒40 days in the long-term safety study. In the post-marketing setting, based on data covering approximately 46,978 patient-years of vedolizumab exposure, post-operative complications were reported in 19 patients.
CONCLUSIONS
CONCLUSIONS
In clinical trials, complications of colectomy and bowel surgery/resection appeared infrequent, with minimal difference between vedolizumab and placebo. The frequency of post-operative complications in the post-marketing setting appears low.
Identifiants
pubmed: 31687151
doi: 10.1093/gastro/goz034
pii: goz034
pmc: PMC6821312
doi:
Types de publication
Journal Article
Langues
eng
Pagination
322-330Informations de copyright
© The Author(s) 2019. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University.
Références
Int J Surg. 2014;12(3):224-30
pubmed: 24394691
Inflamm Bowel Dis. 2017 Dec;23(12):2197-2201
pubmed: 28858072
J Clin Gastroenterol. 2016 Nov/Dec;50(10):803-818
pubmed: 27741097
World J Gastrointest Surg. 2016 Mar 27;8(3):274-83
pubmed: 27022455
Clin Colon Rectal Surg. 2010 Dec;23(4):269-73
pubmed: 22131897
N Engl J Med. 2013 Aug 22;369(8):699-710
pubmed: 23964932
Clin Colon Rectal Surg. 2013 Jun;26(2):80-3
pubmed: 24436654
J Crohns Colitis. 2018 Apr 27;12(5):538-545
pubmed: 29718245
Gastroenterol Rep (Oxf). 2019 Apr;7(2):77-90
pubmed: 30976420
J Crohns Colitis. 2017 Feb;11(2):185-190
pubmed: 27543504
N Engl J Med. 2013 Aug 22;369(8):711-21
pubmed: 23964933
Medicina (Kaunas). 2014;50(2):111-7
pubmed: 25172605
Inflamm Bowel Dis. 2012 Nov;18(11):2107-19
pubmed: 22419649
Gastroenterology. 2014 Sep;147(3):618-627.e3
pubmed: 24859203
J Crohns Colitis. 2016 Dec;10(12):1437-1444
pubmed: 27252400
Aliment Pharmacol Ther. 2018 Mar;47(5):573-580
pubmed: 29250800
Inflamm Bowel Dis. 2015 Nov;21(11):2658-72
pubmed: 26422516
J Crohns Colitis. 2017 Apr 1;11(4):400-411
pubmed: 27683800
J Pharmacol Exp Ther. 2009 Sep;330(3):864-75
pubmed: 19509315
J Crohns Colitis. 2017 Jan;11(1):53-59
pubmed: 27402915
Inflamm Bowel Dis. 2018 Mar 19;24(4):871-876
pubmed: 29509927
Drug Healthc Patient Saf. 2013;5:79-99
pubmed: 23569399
Ther Adv Drug Saf. 2013 Oct;4(5):211-9
pubmed: 25114782
Aliment Pharmacol Ther. 2013 Jun;37(11):1057-64
pubmed: 23581515
J Crohns Colitis. 2017 Oct 27;11(11):1353-1361
pubmed: 28981886
Dan Med J. 2014 Dec;61(12):A4975
pubmed: 25441731
Inflamm Bowel Dis. 2013 Jul;19(8):1691-9
pubmed: 23591599
Am J Gastroenterol. 2008 Sep;103(9):2373-81
pubmed: 18616660
Ann Surg. 2011 Dec;254(6):907-13
pubmed: 21562405
Am J Gastroenterol. 2017 Sep;112(9):1423-1429
pubmed: 28719595
Inflamm Bowel Dis. 2012 Dec;18(12):2404-13
pubmed: 22467533